958 results on '"Reubi, Jean"'
Search Results
2. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands:Synthesis and Preclinical Profile
3. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands: Synthesis and Preclinical Profile
4. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist
5. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [ 111 In]In-Radioligands: Synthesis and Preclinical Profile.
6. Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging
7. Somatostatin receptors in GtoPdb v.2023.1
8. Supplementary Data from Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
9. Supplementary Table 1 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
10. Supplementary Table 3 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
11. Supplementary Table 2 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
12. Data from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
13. Supplementary Figures 1-4 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
14. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
15. Old and New Peptide Receptor Targets in Cancer: Future Directions
16. [DOTA]Somatostatin-14 analogs and their 111In-radioligands: Effects of decreasing ring-size on sst1–5 profile, stability and tumor targeting
17. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
18. Expression of Somatostatin Receptors in Human Tissues in Health and Disease
19. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study
20. Neurotensin receptors in pancreatic ductal carcinomas
21. Phosphorylation of sst2 Receptors in Neuroendocrine Tumors after Octreotide Treatment of Patients
22. Radiopeptide Targeting for Tumor Therapy: Peptide Receptor Distribution
23. Neuropeptide Y acts within the rat testis to inhibit testosterone secretion
24. Radiolabeled Somatostatin Receptor Antagonists Are Preferable to Agonists for in Vivo Peptide Receptor Targeting of Tumors
25. Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors
26. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
27. Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues
28. 64Cu- and 68Ga-Labelled [Nle14,Lys40(Ahx-NODAGA)NH2]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats
29. Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model
30. Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy
31. Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET/CT
32. Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET/CT
33. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
34. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy
35. Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies
36. Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues
37. Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers
38. Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides
39. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607
40. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607
41. Value of the radiolabelled GLP-1 receptor antagonist exendin(9–39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans
42. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
43. Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue
44. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog
45. Early over-expression of GRP receptors in prostatic carcinogenesis
46. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours
47. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment
48. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
49. Peptide receptor expression in GEP-NET
50. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.